SenesTech, Inc. - Common Stock (SNES)

E-commerce revenue surged 186% sequentially as management pivots to direct sales.

SenesTech SNES Q1 2026 Earnings Call Transcript

SenesTech (SNES) Q4 2025 Earnings Call Transcript

SenesTech Q3 2025: Record revenue & strong product growth, but stock fell after a revenue miss. EPS beat estimates, showing improved cost control.

A discussion about the $4B rodent control market and the company’s game-changing product Evolve – a revolutionary form of rodent birth control.

SenesTech, an under-the-radar biotech company with a focus on solving the global pest population problem through, humane fertility control measures, seems attractively valued.

With no direct competition in the fertility control space and growing demand for non-lethal rodent management, could SNES be the next big winner? Find out in this deep-dive conversation with CEO Joel Fruendt.

SenesTech shares lower as they exercise outstanding warrants for 374,718 shares at reduced price, plans to use proceeds for corporate purposes.